🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Frankfurt am Main
Clinical trial register · Germany

Clinical Trials in Frankfurt am Main, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals22 AbbVie19 AstraZeneca15 Janssen Research & Development, LLC13 Eli Lilly and Company12
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Frankfurt am Main

348 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
NCT07234877Non Small Cell Lung Cancer
DrugsPaclitaxel-albumin·Ivonescimab·Pemetrexed·Paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
158
Frankfurt am Main, Jena, Rostock
2026-11
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
Gerlingen, Ulm, Wangen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne
2026-09-30
Not yet open
External Beam Radiotherapy Combined With Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients With Rectal Cancer
NCT06729645Rectal Cancer
University Hospital of Cologne
Not applicable
80
Kempten, Frankfurt am Main, Cologne, Leipzig
2026-09-30
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
DrugsVVD-133214·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 2
140
Ulm, Schweinfurt, Hamburg, Frankfurt am Main, Oldenburg, Essen, Berlin
2026-09-11
Not yet open
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
NCT07788586Candidemia, Invasive Candidiasis
Oliver Cornely, MD
Phase 4
420
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen
2026-09
Recruiting
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
NCT07612267Lactation, Inflammatory Bowel Disease
DrugMirikizumab
Eli Lilly and Company
Phase 4
14
Frankfurt am Main, Potsdam
2026-08-05
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Datopotamab deruxtecan·Opdivo
AstraZeneca
Phase 3
915
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne
2026-07-16
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
Berlin, Essen, Frankfurt am Main, Würzburg
2026-07-08
Recruiting
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT07672236Head & Neck Cancer, Oral Mucositis
OncoZenge AB
Phase 3
150
Cologne, Frankfurt am Main, Freiburg im Breisgau, Kiel, Tübingen
2026-07-07
Not yet open
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
NCT07507968Esophagogastric Adenocarcinoma
DrugDurvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
101
Berlin, Cologne, Essen, Frankfurt am Main, Göttingen, Halle, Hamburg, Heidelberg
2026-07-01
Recruiting
Testing the Effectiveness of Process Based Therapy in Routine Patient Care and Assessing Its Influence on Therapist Decision Making
NCT07704138Depressive and Anxiety Disorders
Goethe University
Not applicable
60
Frankfurt am Main
2026-06-27
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
Erlangen, Frankfurt am Main, Marburg, Cologne, Düsseldorf, Homburg, Berlin
2026-06-02
Recruiting
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
NCT07387198Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
135
Heidelberg, Mannheim, Tübingen, Regensburg, Würzburg, Hamburg, Frankfurt am Main, Bielefeld
2026-05-29
Recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 2
60
Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Regensburg
2026-05-20
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Heidelberg, Tübingen, Potsdam, Frankfurt am Main, Göttingen, Dresden, Berlin
2026-05-17
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Mannheim, Muehldorf Am Inn, Munich, Weiden in Der Oberpfalz, Frankfurt am Main, Hanover, Cologne, Essen
2026-05-11
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Frankfurt am Main
2026-05-06
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Frankfurt am Main, Erlangen
2026-04-28
Recruiting
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
NCT07548944Retinitis Pigmentosa (RP), Usher Syndrome, Cone Rod Dystrophy
Okuvision GmbH
Observational
30
Frankfurt am Main
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Berlin, Cologne, Essen, Frankfurt am Main
2026-04-17
Not yet open
Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)
NCT07497321Pelvic Organ Prolapse (POP), Synthetic Mesh, Laparoscopic Surgery, Gynecologic Laparoscopic Surgery
A.M.I. Agency for Medical Innovations GmbH
Not applicable
100
Erlangen, Hausham, Frankfurt am Main
2026-04-15
Recruiting
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
NCT07523620Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
240
Frankfurt am Main, Lübeck, Berlin
2026-03-31
Recruiting
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT07293260Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
406
Berlin, Essen, Frankfurt am Main, München
2026-03-23
Recruiting
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT07194382Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
160
Munich, Frankfurt am Main
2026-03-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
DrugsINCA33890·Folfox·Bevacizumab
Incyte Corporation
Phase 3
700
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Lübeck
2026-03-05
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Freiburg im Breisgau, Frankfurt am Main, Düsseldorf
2026-01-30
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Acalabrutinib·Zanubrutinib·Venetoclax
BeOne Medicines
Phase 3
500
Deggendorf, Frankfurt am Main, Münster, Straubing
2026-01-22
Recruiting
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
NCT07025824AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
DrugsTreosulfan·Melphalan·Fludarabine
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping
NCT07320560Atrial Fibrillation (AF)
German Heart Institute
Not applicable
45
Berlin, Frankfurt am Main
2026-01-15
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Berlin, Bonn, Detmold, Dresden, Düsseldorf, Essen, Frankfurt am Main, Hamburg
2025-12-29
Recruiting
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
NCT07510724Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Observational
240
Frankfurt am Main
2025-12-23
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Löwenstein, Frankfurt am Main, Giessen, Cologne
2025-12-22
Recruiting
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
NCT06722183Colorectal Cancer
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
33
Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München
2025-12-16
Recruiting
REFOCUS-AF - "RepEat Ablation With AFFERA vs. COntact Force-Guided RF Catheters for Optimal OUtcomes in Symptomatic AF".
NCT07390214Atrial Fibrillation - Symptomatic
Cardioangiologisches Centrum Bethanien
Not applicable
200
Frankfurt am Main
2025-12-15
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Frankfurt am Main, Leipzig, Berlin, Dresden, Hamburg, München
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
Frankfurt am Main, Rostock, Bonn, Berlin, Hamburg
2025-12-11
Recruiting
Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)
NCT06914544Prostate Cancer
University Hospital Schleswig-Holstein
Not applicable
175
Frankfurt am Main, Munich, Kiel, Erfurt
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Homburg, Berlin, Frankfurt am Main, Mannheim
2025-12-10
Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999Small Cell Lung Cancer (SCLC)
DrugsPF-08634404·Atezolizumab
Pfizer
Phase 2/3
550
Düsseldorf, Frankfurt am Main
2025-12-09
Active, closed
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
160
Heidelberg, Frankfurt am Main, Bad Bentheim, Kiel
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
Deggingen, München, Frankfurt am Main, Witten, Leipzig, Lübeck, Berlin
2025-12-03
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Munich, Potsdam, Frankfurt am Main, Kaiserslautern, Dresden, Bad Krozingen, Bad Oeynhausen, Berlin
2025-12-02
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Frankfurt am Main, Berlin, Dresden, Halle
2025-11-30
Recruiting
Dynamic Network Response to TMS Treatment
NCT07422844MDD
Goethe University
Observational
100
Frankfurt am Main
2025-11-24
Recruiting
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
NCT07026474Recurrent Head and Neck Squamous Cell Carcinoma
DrugsAdrucil·Cisplatin·Pembrolizumab
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Ahaus, Bonn, Düsseldorf, Frankfurt am Main, Marburg, Würzburg
2025-10-28
Recruiting
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
NCT06856837Metastatic Colorectal Cancer
DrugsLonsurf·Trifluridine/Tipiracil·Fruquintinib·Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
140
Amberg, Bad Saarow, Berlin, Bochum, Düsseldorf, Essen, Frankfurt, Frankfurt am Main
2025-10-27
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Recruiting
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
48
Berlin, Frankfurt am Main, Munich
2025-10-16
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Frankfurt am Main
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
DrugsPF-08046054·Docetaxel
Pfizer
Phase 3
680
Heidelberg, Stuttgart, Hösbach, Frankfurt am Main, Giessen, Immenhausen, Kassel, Bonn
2025-09-29
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Ahrensburg, Augsburg, Berlin, Darmstadt, Frankfurt, Frankfurt am Main, Hamburg, Leipzig
2025-09-16
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Esslingen am Neckar, Augsburg, München, Frankfurt am Main, Langen, Hanover, Düsseldorf, Essen
2025-09-11
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
München, Frankfurt am Main, Halle, Cologne, Würzburg
2025-09-09
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Braunschweig, Duisburg, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Heidelberg, München
2025-09-02
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Großhansdorf, Kiel
2025-08-18
Recruiting
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
NCT07059000Chronic Primary Immune Thrombocytopenia (ITP)
DrugKedrion IVIG
Kedrion S.p.A.
Phase 3
40
Donauwörth, Frankfurt am Main
2025-08-13
Recruiting
SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70
NCT06961578Odontoid Fracture, Elderly
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Recruiting
Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions.
NCT07008261Transfusions, Cystectomy, Blood Loss Requiring Transfusion, Anaemia
Goethe University
Observational
60
Frankfurt am Main
2025-08-01
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Active, closed
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07128550Viral Hepatitis
DrugsTobevibart·Bulevirtide·Elebsiran
Vir Biotechnology, Inc.
Phase 3
150
Berlin, Essen, Frankfurt am Main, Hanover
2025-07-30
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz
2025-07-24
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin
2025-07-21
Recruiting
Treatment Monitoring for NTM Infections With a Symptom Diary
NCT07131774Non-Tuberculous Mycobacterial (NTM) Infections
Research Center Borstel
Observational
200
Freiburg im Breisgau, Frankfurt am Main, Borstel
2025-07-11
Active, closed
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
DrugVerekitug
Upstream Bio Inc.
Phase 2
666
Aschaffenburg, Augsburg, Bamberg, München, Cottbus, Hamburg, Darmstadt, Frankfurt am Main
2025-07-02
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-30
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-27
Recruiting
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
NCT06717958AML, MDS
DrugIvosidenib
Technische Universität Dresden
Phase 2
76
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt am Main, Greifswald, Halle
2025-06-17
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsRisankizumab·Vedolizumab
AbbVie
Phase 3
573
Freiburg im Breisgau, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main, Essen, Minden
2025-06-17
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Frankfurt am Main, Berlin
2025-06-09
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Frankfurt am Main, Leipzig, Hamburg
2025-06-02
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Heidelberg, Frankfurt am Main, Cologne, Essen, Hamburg
2025-05-29
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Berlin, Brandenburg an der Havel, Dachau, Frankfurt am Main, Kiel, Leipzig, Munich, Ulm
2025-05-27
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg
2025-05-22
Recruiting
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830Hemophilia A
DrugEfanesoctocog alfa
Swedish Orphan Biovitrum
Phase 4
250
Berlin, Bonn, Frankfurt am Main, Hamburg, Munich
2025-05-21
Recruiting
Towards a More Standardized Bicuspid Aortic Valve Repair: Rationale and Design of CONTOUR Trial - a Randomized Trial
NCT06869954Bicuspid Aortic Valve (BAV), Aortic Regurgitation Disease
University Hospital Augsburg
Not applicable
100
Augsburg, Frankfurt am Main, Leipzig, Hamburg
2025-05-21
Recruiting
Effects of Frontopolar TMS in Alcohol Craving
NCT07064590Alcohol Addiction
Goethe University
Not applicable
34
Frankfurt am Main
2025-05-16
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
350
Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main, Bad Bentheim
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Frankfurt am Main, Cologne, Duisburg, Lübeck
2025-05-13
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Heidelberg, Villingen-Schwenningen, Frankfurt am Main, Mainz, Dresden, Leipzig, Berlin
2025-05-08
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246Intracerebral Hemorrhage
DrugRecombinant Factor VIIa
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne
2025-04-24
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Stuttgart, Tübingen, Ulm, Erlangen, Munich, Würzburg, Frankfurt am Main, Kassel
2025-04-11
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Berlin, Bonn, Cottbus, Delitzsch, Frankfurt am Main, Geesthacht, Hemer, Landsberg
2025-03-28
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Active, closed
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
NCT06731803Esophagogastric Adenocarcinoma
DrugTrastuzumab deruxtecan
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Amberg, Augsburg, Bad Saarow, Berlin, Cologne, Frankfurt, Frankfurt am Main, Gauting
2025-03-21
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Recruiting
The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction
NCT06874426Meningioma, Pituitary Disease, Pituitary Adenoma, Craniopharyngioma
Universitaire Ziekenhuizen KU Leuven
Observational
154
Frankfurt am Main
2025-03-18
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Freiburg im Breisgau, Heilbronn, Augsburg, Würzburg, Frankfurt am Main, Cologne, Hemer, Oldenburg in Holstein
2025-03-06
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 3
300
Chemnitz, Frankfurt am Main, Halle, Hamburg, Mutlangen, München, Siegen
2025-03-05
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
9
Frankfurt am Main
2025-02-28
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Frankfurt am Main, Oldenburg, Cologne, Halle, Bad Berka, Gauting, Großhansdorf, Heidelberg
2025-02-25
Rows per page Showing 1–100 of 348
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/frankfurt-am-main

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 348 of those studies with a site in Frankfurt am Main.

How many clinical trials are recruiting in Frankfurt am Main?

174 of the 348 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 6 have not yet opened recruitment, 161 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Frankfurt am Main), 348 studies
PhaseStudiesRecruitingShare
Phase 31727049.4%
Phase 2613417.5%
Observational463113.2%
Not applicable26187.5%
Phase 1/220105.7%
Phase 41062.9%
Phase 2/3732%
Phase 1621.7%

Most active sponsors

Lead sponsors with the most studies (Frankfurt am Main)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals2211
AbbVie194
AstraZeneca157
Janssen Research & Development, LLC134
Eli Lilly and Company126
Goethe University129
Merck Sharp & Dohme LLC126
Pfizer107
Regeneron Pharmaceuticals95
Incyte Corporation72
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.